News
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
What's New: Drugs RSS Feed · By FDA ·
The Brief
- On April 18, 2024, the FDA approved alectinib (Alecensa, Genentech) as adjuvant treatment following tumor resection.
- The approval covers patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
- Eligibility depends on the ALK-positive status being detected by an FDA-approved test.
Why it matters
It extends alectinib from advanced disease to use after surgical removal of the tumor in ALK-positive NSCLC, a change that affects how patients in this setting may be treated.
Who’s affected
- Patients with ALK-positive NSCLC who have had tumor resection
- #oncology
- #lung-cancer
- #alectinib
- #drug-approval
- #fda
On April 18, 2024, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.
Timeline
FDA approved alectinib as adjuvant treatment following tumor resection in ALK-positive NSCLC
What's New: Drugs RSS Feed
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer